In This Article:
-
Annual Recurring Revenue (ARR): Grew 25% year-over-year to $396 million.
-
Free Cash Flow: $122 million for the full year 2024.
-
Adjusted EBITDA Margin: 25% for the full year 2024.
-
Revenue: $401.2 million for the full year 2024, a 23% increase from the previous year.
-
Gross Margin: 85% for the full year 2024, up from 84.2% in 2023.
-
Net Income: Non-GAAP net income of $97.8 million for 2024.
-
Cash Position: Ended 2024 with $483.8 million in cash, cash equivalents, and investments.
-
Operating Expenses: $65.1 million in Q4, a 13% year-over-year increase.
-
Subscription Software Revenue: Increased by 26% for the full year 2024.
-
Guardian ARR Growth: Triple-digit percentage growth year-over-year in the second half of 2024.
-
Pathfinder ARR Growth: Year-on-year ARR expansion in the 35% to 50% range.
-
Cloud-based ARR: Nearly doubled to 17% of total ARR in 2024.
-
2025 ARR Outlook: Expected to range from $480 million to $495 million, a 21% to 25% increase over 2024.
-
2025 Revenue Outlook: Expected to range from $480 million to $490 million, a 20% to 22% growth over 2024.
-
2025 Adjusted EBITDA Outlook: Expected to range from $113 million to $123 million, or 24% to 25% of total revenue.
Release Date: February 13, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Cellebrite DI Ltd (NASDAQ:CLBT) exceeded its original revenue and adjusted EBITDA targets for 2024, delivering at the higher end of ARR expectations.
-
The company achieved a Rule of 50 performance with 25% ARR growth and 25% adjusted EBITDA margins.
-
Cellebrite DI Ltd (NASDAQ:CLBT) generated $122 million in free cash flow in 2024, showcasing strong cash generation.
-
The company reported significant growth in its Guardian and Pathfinder solutions, with Guardian ARR generating triple-digit percentage growth year-over-year.
-
Cellebrite DI Ltd (NASDAQ:CLBT) achieved FedRAMP ready status, enhancing its potential to expand within the US federal sector.
Negative Points
-
The CEO search is ongoing, with no specific timeline for the appointment of a new leader.
-
There are modest headwinds due to geopolitical changes and regime disruptions in the US and Europe.
-
The company faces challenges in expanding its customer base in certain countries, impacting growth retention rates.
-
Cellebrite DI Ltd (NASDAQ:CLBT) anticipates a modest impact on Q1 2025 results due to decisions to exit certain countries.
-
The magnitude of the EBITDA beat in Q4 2024 was lower than in previous quarters, with guidance for Q1 2025 in line with expectations.